AR067873A1 - Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3 - Google Patents
Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3Info
- Publication number
- AR067873A1 AR067873A1 ARP080103450A ARP080103450A AR067873A1 AR 067873 A1 AR067873 A1 AR 067873A1 AR P080103450 A ARP080103450 A AR P080103450A AR P080103450 A ARP080103450 A AR P080103450A AR 067873 A1 AR067873 A1 AR 067873A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ht2a
- receptors
- haloalkyl
- group
- Prior art date
Links
- 230000009977 dual effect Effects 0.000 title abstract 2
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 title 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 2
- 101150104779 HTR2A gene Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- -1 hydroxy C1-6 alkyl Chemical group 0.000 abstract 2
- 229940076279 serotonin Drugs 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 abstract 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Moduladores duales de los receptores de la serotonina 5-HT2a y de la dopamina D3, su obtencion, las composiciones farmacéuticas que los contienen y su utilizacion como medicamentos. Los compuestos de general formula (1) tienen una gran afinidad con los receptores de la dopamina D3 y de la serotonina (5-hidroxitriptamina; 5-HT) 5-HT2a y son eficaces para el tratamiento de trastornos psicoticos, así como otros trastornos, tales como la depresion y la ansiedad, la dependencia de fármacos, las demencias y los desequilibrios de memoria. Reivindicacion 1: un compuesto de la formula (1) en la que R1: es un resto de la formula (2) A es arilo o heteroarilo de 5 o 6 eslabones opcionalmente sustituido de una a cinco veces por sustituyentes elegidos entre el grupo formado por ciano, halogeno, alquilo C1-6, haloalquilo C1-6 y alcoxi C1-6; m es el numero 1, 2 o 3; n es el numero 1, 2, 3, 4 o 5; o es el numero 0, 1 o 2; R2 se elige entre el grupo formado por hidrogeno, hidroxilo alquilo C1-6, haloalquilo C1-6 y alcoxi C1-6; R3 se elige entre el grupo formado por hidrogeno, con la condicion de que R2 es distinto hidrogeno hidroxilo; alquilo C1-6; haloalquilo C1-6 haloalcoxi C1-6 oxo; -NR(CO)-alquilo C1-6; -O-alquilo C1-6; -O-cicloalquilo C3-7; y -O-(heterocicloalquilo de 3 a 7 eslabones); así como las sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114119 | 2007-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067873A1 true AR067873A1 (es) | 2009-10-28 |
Family
ID=39865594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103450A AR067873A1 (es) | 2007-08-09 | 2008-08-07 | Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8097637B2 (es) |
| EP (1) | EP2185513B1 (es) |
| JP (1) | JP5296073B2 (es) |
| KR (1) | KR101171467B1 (es) |
| CN (1) | CN101778820B (es) |
| AR (1) | AR067873A1 (es) |
| AT (1) | ATE512137T1 (es) |
| AU (1) | AU2008285729B2 (es) |
| BR (1) | BRPI0814999A2 (es) |
| CA (1) | CA2694057A1 (es) |
| CL (1) | CL2008002310A1 (es) |
| ES (1) | ES2366766T3 (es) |
| MX (1) | MX2010001195A (es) |
| PE (1) | PE20090513A1 (es) |
| TW (1) | TW200914422A (es) |
| WO (1) | WO2009019174A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2640807A1 (en) * | 2006-02-17 | 2007-08-23 | F. Hoffmann-La Roche Ag | Benzoyl-piperidine derivatives as 5ht2/d3 modulators |
| ES2498673T3 (es) * | 2007-07-26 | 2014-09-25 | F. Hoffmann-La Roche Ag | Moduladores duales de los receptores 5-HT2a y D3 |
| US8586579B2 (en) | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8470828B2 (en) | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8921397B2 (en) * | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| EP2809156B1 (en) | 2011-12-08 | 2017-05-24 | The Board of Regents of The University of Texas System | Allosteric modulators of 5-hydroxytryptamine 2c receptor (5-ht2cr) |
| EP3744713A1 (en) | 2014-12-12 | 2020-12-02 | Japan Tobacco Inc. | Diyhydropyrimidine-2-one compounds and medicinal uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2717479B1 (fr) * | 1994-03-18 | 1996-06-07 | Pf Medicament | Nouvelles 3-(omega-benzoylpipéridino) alcoyl)-4H-Benzopyran-4-ones, leur préparation et leur application en thérapeutique. |
| HUP0103986A2 (hu) * | 2001-09-28 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| JPWO2003053928A1 (ja) * | 2001-12-13 | 2005-04-28 | 住友製薬株式会社 | セロトニン再取り込み阻害剤 |
| CA2640807A1 (en) * | 2006-02-17 | 2007-08-23 | F. Hoffmann-La Roche Ag | Benzoyl-piperidine derivatives as 5ht2/d3 modulators |
-
2008
- 2008-07-30 JP JP2010519432A patent/JP5296073B2/ja not_active Expired - Fee Related
- 2008-07-30 MX MX2010001195A patent/MX2010001195A/es active IP Right Grant
- 2008-07-30 AU AU2008285729A patent/AU2008285729B2/en not_active Ceased
- 2008-07-30 KR KR1020107002763A patent/KR101171467B1/ko not_active IP Right Cessation
- 2008-07-30 CN CN2008801026707A patent/CN101778820B/zh not_active Expired - Fee Related
- 2008-07-30 BR BRPI0814999-2A2A patent/BRPI0814999A2/pt not_active Application Discontinuation
- 2008-07-30 ES ES08786606T patent/ES2366766T3/es active Active
- 2008-07-30 CA CA2694057A patent/CA2694057A1/en not_active Abandoned
- 2008-07-30 WO PCT/EP2008/059971 patent/WO2009019174A1/en active Application Filing
- 2008-07-30 EP EP08786606A patent/EP2185513B1/en not_active Not-in-force
- 2008-07-30 AT AT08786606T patent/ATE512137T1/de active
- 2008-08-01 US US12/184,272 patent/US8097637B2/en not_active Expired - Fee Related
- 2008-08-06 CL CL2008002310A patent/CL2008002310A1/es unknown
- 2008-08-07 AR ARP080103450A patent/AR067873A1/es unknown
- 2008-08-07 PE PE2008001318A patent/PE20090513A1/es not_active Application Discontinuation
- 2008-08-08 TW TW097130407A patent/TW200914422A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2185513A1 (en) | 2010-05-19 |
| JP5296073B2 (ja) | 2013-09-25 |
| ATE512137T1 (de) | 2011-06-15 |
| EP2185513B1 (en) | 2011-06-08 |
| BRPI0814999A2 (pt) | 2015-02-03 |
| CL2008002310A1 (es) | 2009-05-29 |
| US8097637B2 (en) | 2012-01-17 |
| JP2010535735A (ja) | 2010-11-25 |
| WO2009019174A1 (en) | 2009-02-12 |
| KR20100029850A (ko) | 2010-03-17 |
| ES2366766T3 (es) | 2011-10-25 |
| AU2008285729A1 (en) | 2009-02-12 |
| MX2010001195A (es) | 2010-03-01 |
| CA2694057A1 (en) | 2009-02-12 |
| PE20090513A1 (es) | 2009-04-29 |
| TW200914422A (en) | 2009-04-01 |
| AU2008285729B2 (en) | 2012-11-01 |
| US20090042943A1 (en) | 2009-02-12 |
| CN101778820B (zh) | 2012-12-05 |
| KR101171467B1 (ko) | 2012-08-07 |
| CN101778820A (zh) | 2010-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
| AR067873A1 (es) | Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3 | |
| AR073622A1 (es) | Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticos | |
| AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR056204A1 (es) | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| AR077505A1 (es) | Compuestos de piridina y sus usos | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| AR060401A1 (es) | Derivados de cromen-2-ona | |
| AR073396A1 (es) | Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| CO6341581A2 (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR059094A1 (es) | Derivados de ciclohexil - sulfonamida | |
| AR082004A1 (es) | Compuestos de fusion de piridina | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| UY30938A1 (es) | Derivados de nicotinamida, sales y solvatos farmacéuticamente aceptables, composiciones y aplicaciones. | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| AR086024A1 (es) | Derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina carboxamidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |